Navigation Links
GEN reports on growing reliance on microfluidics technology
Date:1/22/2009

New Rochelle, NY, January 22, 2009--Biotechnology companies are building on what they have learned about microfluidics techniques over the past decade and are expected to drive this market toward $1.9 billion in three years, reports Genetic Engineering and Biotechnology News (GEN); (www.genengnews.com). The technology offers a number of advantages, including reducing reagent consumption, increasing speed and analytical performance, multiparameter testing, and user friendliness, according to the January 15 issue of GEN.

"The globalization of life science research and an increasing trend toward novel diagnostic development, particularly point of care, are providing a significant boost toward a greater acceptance of microfluidics methodologies," says John Sterling, Editor in Chief of GEN.

Much of drug discovery focuses on finding inhibitors of enzyme targets such as kinases, phosphatases, and proteases. Caliper Life Sciences created its Mobility Shift Assay to interrogate druggable enzymes. It combines the advantages of capillary electrophoresis with microfluidics technology for the direct measurement of substrate and product.

Biosite has developed protein array technologies that contain microcapillaries for controlling the flow of fluids in immunoassay processes. The protein array format uses several different microcapillary designs to control the contact of sample with reagents and to direct the flow of fluid throughout the protein array. For example, after a blood sample is added to the array, a special internal filter separates cells from plasma. Next a capillary directs the sample into a chamber that contains dried immunoassay reagents. After an incubation time that is determined by another microcapillary element of the array, the sample next flows down a capillary path and interacts with an antibody array. The interactions are detected in the company's Triage M
'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1 2

Related biology news :

1. BIO-key Reports Second Quarter 2007 Results
2. Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
3. Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia
4. BIO-key Reports Third Quarter 2007 Results
5. WHRC releases 4 key reports
6. Rong Li Lab reports protein interactions of MAP kinase signaling pathway
7. UVA reports surprising findings related to myotonic muscular dystrophy
8. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
9. MIT reports new twist in microRNA biology
10. Aware, Inc. Reports Fourth Quarter and 2007 Financial Results
11. Genetic Engineering & Biotechnology News reports on advances in miRNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced ... the APAC Region 2015-2019"  report to their offering. ... this market is advances in technology. With continuous ... biometric solutions to the latest standard that meets ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... has shown a normalizing effect of platelet-endothelial cell alterations ... Cyclooxygenase 2 inhibition. This study, ... is described in a research article to be published ... of Gastroenterology. Portal hypertension is a major complication ...
... U.S. Department of Energy,s Argonne National Laboratory is ... toward the goal of creating a cleaner Beijing ... Games and beyond. Recently, DOE and ... five-year agreement aimed at promoting large scale deployment ...
... an Indiana University environmental science professor and several colleagues ... has the potential to harm aquatic ecosystems. The study ... Proceedings of the National Academies of Sciences . ... professor in the IU School of Public and Environmental ...
Cached Biology News:Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension 2Argonne helps China create cleaner Beijing for 2008 Olympics 2Study shows genetically engineered corn could affect aquatic ecosystems 2Study shows genetically engineered corn could affect aquatic ecosystems 3
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Antipsychotic Agent with Less Potential for ... and Metabolic Risks, SAN DIEGO, July 29 ... the United States Patent and,Trademark Office (USPTO) issued a ... broad coverage for a pharmaceutical,composition of zonisamide in combination ...
... up to 50% sucrose reduction while maintaining the sweet taste ... ... July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), a leading ... ingredients for the food, beverage,and ingredient supply industries, announced today that ...
... July 29 Zenobia Therapeutics, Inc.,(Zenobia) announced ... Development,Initiative award from The Michael J. Fox ... research with potential to,fundamentally alter the course ... Dr. Christopher Ross of Johns Hopkins University,Zenobia ...
Cached Biology Technology:OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2
Request Info...
... of Printing Surface (3 glass slides coated with 100 ... silicon wafer coated with 1000 Angstroms of Gold over ... PDMS Stamps (3 PDMS micropatterned stamps with series of ... 10 mm or 200 um x 10 mm lines, ...
LTBP-1 (E-20)...
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Biology Products: